

# Microdosing: A Guide to Using Buprenorphine During the Illicit Fentanyl Pandemic



UNIVERSITY OF MINNESOTA

**Driven to Discover<sup>SM</sup>**

Ryan Kelly and Jesse Bennett

# Presenter Backgrounds

## JESSE BENNETT

- Executive Director for the North Carolina Harm Reduction Coalition
- Certified in integrated harm reduction psychotherapy
- Participates in the implementation of harm reduction interventions, public health strategies, drug policy transformation, and justice reform

## RYAN KELLY

- MedPeds primary care and Addiction at the Community-University Health Care Center
- Medicine Hospitalist, Addiction and Harm Reduction Consultant, University of Minnesota Medical Center
- Board, South Side Harm Reduction (SSP)
- Addiction Medicine Credentialed, 2020



# Disclosure Information

- **Disclosure of Relevant Financial Relationships**

None



# Outline/Objectives

## OUTLINE

- Physiology of Opioid use disorder and MAT
- Classic induction when heroin was heroin
  - Hospital experience
- The synthetic (fentanyl) opioid crisis
  - Challenges with classic induction
- Bernese Method; US challenges in implementation
- Our experience with micro-inductions

## OBJECTIVES

- Understand how buprenorphine works, and when microinductions might be helpful
- Understand new challenges with buprenorphine induction and precipitated withdrawal
- List two methods for a patient to start taking buprenorphine including microinductions



# Definitions

- **Microdosing:** Starting buprenorphine at tiny doses, assuming the patient will need agonist opioids for the first few days (similar to Bernese method)
- **Classic induction:** period of withdrawal, followed by a 2-4 mg dose of buprenorphine
- **Low dose classic induction:** period of withdrawal, followed by taking small doses of Suboxone film throughout the day, until symptoms improve, and then taking full dose of buprenorphine
- **Macrodosing:** once someone is in withdrawal, giving doses over several hours to a peak of 32 mg, to overcome precipitated withdrawal




# The problem

---

OPIOID RELATED DEATHS ARE RISING; WE DON'T KNOW WHAT'S IN DOPE; STARTING BUPE IS TRICKIER!

## Drug overdose deaths by non-exclusive drug category, MN residents, STATEWIDE, 2011-2020



# Deaths in NC

The rate of unintentional overdose deaths among residents of NC in 2020


(Annual) was **22.1**.

(Rate per 100,000 residents. Number of deaths: 2,322)

## Place Rank

**NA**

(NC has no comparison group)\*



NC DEPARTMENT OF  
HEALTH AND  
HUMAN SERVICES



UNIVERSITY OF MINNESOTA

Driven to Discover<sup>SM</sup>

# Injected Related Infections

BACTERIA ON OUR SKIN AND IN OUR MOUTHS:

- Cellulitis, Abscess, Sepsis, Osteomyelitis, Endocarditis
- Viruses:
  - HIV, hep C, hep A

TECHNIQUE: WITHOUT TRAINING ON SAFER INJECTION TECHNIQUE, AND/OR LACK OF ACCESS TO SUPPLIES:

- Licking needles
- Improper skin cleaning
- Re-using syringes
- Sharing needles
- Re-using rinses
- The more injections, the increased risk






#### Supplies:

1. **Clean Bottle** for mixing water and bleach
2. **Bleach** to disinfect used syringes when a clean one isn't available
3. **Bandages** to help avoid infection after injecting
4. **Sterile water** to mix the drug with
5. **Tourniquet** to "tie off" above the injection site.
6. **Bottle cap** for mixing water with the drug before it's drawn up into the syringe (commonly called "cooker")
7. **Cotton balls** to trap dirt and debris as the drug, mixed in water, is pulled into the syringe.
8. **Syringes** don't come inside the kit but are provided at distribution sites.
9. **Step-by-step injection instructions**
10. **Alcohol swabs** to clean the injection site before insertion.

#### STEPS:

- Clean surface
- Wash hands
  - Mix drug ("cooking")
- Draw through filter (also called a rinse)
  - Don't share rinses
  - Discuss risk of re-using
- Find site (at least 1 inch from last site), clean skin
- Tourniquet
- Inject (don't lick needle!)
- Band aid

**ASK ABOUT PREP AND PEP FOR HIV**



#### TIPS:

##### 1. Water:

- Don't use water that's been sitting out uncovered.
- If you are using bottled water, put the cap back on after taking the amount you need out.
- Use the sterile needle to draw the water out and immediately cap it.
- Boiling water and letting it cool sterilizes it.
- Tap water which has been running is better than water that's been sitting out exposed to air.

2. Alcohol Swabs: clean the injection area and before actually injecting do one decisive swabs in one direction with a new swab. Don't rub around or go back and forth because you're just moving bacteria back into the injection site.

##### 3. Tie/Tourniquet:

- Remove the tie before pushing the plunger in.
- Always use a tie; the vein is more accessible and easier to hit.

4. If you miss, use a new needle if you can. The sharper the better and they get dull quick

##### 5. Rotate injection sites

##### 6. Cleaning rig:

- If you rinse a rig with bleach, rinse it again with cold water.
- Always use cold water- Warm water causes blood to clot and doesn't do as good a job washing the bleach away
- Don't boil syringes

7. If you have a stock of water, only use brand new needles to draw up water to put in a cooler. Don't put a rig you or someone else has already used back into the clean water, as that will contaminate it.



**Driven to Discover<sup>SM</sup>**

## Synthetic Opioid Crisis:

- Fentanyl can lead to:
- More withdrawal frequency
- More frequent injections=
  - Higher Bacterial Burden
  - Increased risk of Overdose
  - Increase in Hospitalizations



# **Big Picture: How does someone become dependent?**



What are some  
solutions?


---

## Medications for Opioid Use Disorder (MAT: ie methadone and buprenorphine products like Suboxone)

- Reduce mortality
- Reduce transmission of blood-borne viruses
- Decrease bacterial infections
- Improve patients' general health and well being (psycho-social functioning)
- Reduce drug-related crime
- Reduce heroin and other drug use



# What is Opioid Maintenance Therapy?



**MOUD options:**  
Methadone  
Buprenorphine products

- On average:
- >90% relapse with abstinence or tapering
  - 1 year mortality after OD decreased 60%

Abstinence or Tapering = RELAPSE



# HOWEVER!!

- If patients take Suboxone (buprenorphine) while other opioids are “on board:”
  - This **CAUSES PRECIPITATED WITHDRAWAL**
    - If someone has opioids on the receptors in their brain that haven’t worn off yet: bupe is so powerful, at a regular dose, it “sucks” the other opioid off the receptor, and the patient goes into immediate severe opioid withdrawal.
- **[THIS IS DUE TO THE BUPRENORPHINE, NOT THE NALOXONE]**
  - Patients traditionally need to be in withdrawal prior to first dose



# “Classic” Home Suboxone induction:

- Wait 24 hours; the opioid (heroin, in the past), has fully worn off.
- The patient is in withdrawal.
- A patient interested in suboxone can:
  - Option 1: go to a clinic that doses suboxone in clinic
  - Option 2: receive a script for “home” (out of clinic) induction
  - (Other options like detox, emergency department will be deferred today)
- Worked well for most people



# Classic Hospital:

## SHORT STAY

- Hold Opioids
- Once COWS more than 8, give 2-4 mg bupe
- Give throughout day based on COWS, to peak of 8 or 16 mg

## LONG STAY OR LOTS OF PAIN

- If on agonist opioids, hold oral dilaudid at 10 pm
- Offer 2 mg bupe at 3 am prn, COWS 8 or higher
- Offer again 2 hours later
- Once tolerated, change to regular dose of bupe



# New challenges with the “classic” method:

- Since 2019:
  - Hospitalized patients started asking for methadone (less access in MN)
  - Patients using syringe exchange “less interested” in suboxone
  - Started hearing “suboxone doesn’t work anymore, since I use fentanyl”
  - Withdrawal symptoms often seem to increase when folks try to start suboxone
  - Realized it was due to precip withdrawal, potentially from illicit fentanyl
  - Conversations on Opioid Safety and Naloxone Network (OSNN) confirmed this



# Why are people who use fentanyl struggling more with suboxone induction?

## THEORIES

- People aren't waiting long enough for first dose: **popular belief among addiction providers**
- People mistake “anxiety” for withdrawal, and are taking suboxone too soon.
- People just need to WAIT longer, “quitting is hard”
- MAYBE there something different about illicit fentanyl?

## REVIEW OF LITERATURE

- Bernese method
- Discussions on OSNN
- I had already started microdosing for people in the hospital on opioids for pain control after heart surgery, and knew it worked



# Question 1:

- What IS illicit fentanyl?
  - How does it get into the drug supply?
  - Every “bag” is different = dope much less predictable
- It is highly lipophilic: it builds up in body fat
  - For some people, this may mean that it can take longer to clear out of the system (research supports this)



# Theory

- Chemical diversity of these products

*plus*

Lipophilic properties

- Fentanyl builds up in a patient's system in unpredictable ways:
  - **In SOME PEOPLE**, A classic induction dose of suboxone:
  - Can lead to precipitated withdrawal long after euphoria has worn off, even after 24 hours of no use.
  - Some providers recommend waiting **72 hours** before starting suboxone



# Question 2: How can medical providers help?

- Based on:
  - Listening to patients
  - Literature
  - Experience in the hospital
  - Support from OSNN
  - Minimal access to methadone for many patients
  - Input from SSPs



# Three main options:

- Wait longer, and use lower initial doses
- Keep using opioids, and titrate up buprenorphine
- Try and overcome withdrawal with High doses (macro dosing)
- And give everyone gabapentin, hydroxyzine, Zofran, and clonidine!



# Microdosing options: Burnese

- Hammig et al, Substance Abuse and Rehabilitation 2016
- Buprenorphine **and street heroin**
- Day 1 0.2 mg SL/2.5 g heroin
- Day 2 0.2 mg SL/ 2 g heroin
- Day 3 0.8+2 mg SL/ 0.5 g heroin
- Day 4 2 +2.5 mg SL/ 1.5 g heroin
- Day 5 2.5+2.5 mg SL/0.5 g heroin
- Day 6 2.5 + 4 mg SL (stop heroin)
- Day 6 4 + 4 mg SL
- Day 7 4 + 4 mg SL
- Day 8 8 + 4 mg SL



# Hospital Inductions:

---

# Hospital:

- Low dose bupe:
  - Options include IV bupe, butrans patch, belbuca (buccal film)



# Hospital: with predicted 5 day stay and lots of pain

- Induction with buccal films, while continuing agonist opioids, with belbuca, a buccal form of buprenorphine:
- day 1: 75 micrograms QID (1/2 of the 150 mcg buccal film)
- day 2 150 microgram QID
- day 3 is 450 microgram QID
- day 4 transition to suboxone 2/0.5 mg films: 1 mg (1/2 a film) QID
- Day 5: 4 mg BID (4/1 mg film)
  - Continue at this dose if needing agonist opioids for **pain**

OR

- Day 6: otherwise stop other opioids and increase to 8-2 mg stop methadone/other opioids vs opioid taper, depending on the patient



# Short stay/No causes of acute pain besides withdrawal:

- Slow Classic Induction:
  - COWS >8
  - Give 1 mg buprenorphine
  - if no precipitated withdrawal:
    - Dose 2 mg bupe Q 2 prn COWS >8, up to 16 mg
  - Next morning, change to 8-2 mg BID if tolerated



# Home Inductions

---

# Assessment:

- Distress tolerance
- Barriers to ongoing use (legal issues, treatment, access, pregnancy status)
- Willingness for ongoing use (some patients are just done)
- Stability (housing, support, use pattern)
- Cognitive ability (understand dosing schedule, ability to follow directions)
- Apprehension and anxiety (withdrawal can be traumatic, precipitated withdrawal is worse)
- **MEET THEM WHERE THEY ARE AT**



# Patient Centered Questions:

- Any precipitated withdrawal recently
- Frequent fentanyl use:
  - I discuss two options:
    - “nibble method”
      - period of withdrawal
      - Followed by taking small doses of Suboxone film throughout the day, until symptoms improve, and then taking full dose of buprenorphine
    - “microdosing”



# Home Microinduction

- Provider info:
  - Day 1: 0.5mg once
  - Day 2: 0.5mg twice a day
  - Day 3: 1mg twice a day
  - Day 4: 2mg twice a day
  - Day 5: 4mg twice a day
  - Day 6: new script, 8-2 mg films
- Script 1: 2-0.5 mg films, one film a day as instructed, total 4 films, 0 refills
- Will need new script for day 5, of 8-2 mg films, 1-2 films daily, total 14 films, 0 refills



## Suboxone (buprenorphine/naloxone) Home Induction Instructions

For some people, the "classic" induction with Suboxone (waiting until withdrawing) isn't helping people feel well. Another method is called microdosing. By slowly increasing the Suboxone in your body every day, some people are able to start Suboxone without going into withdrawal.

**you may need to use your usual substances for the first few days to control withdrawal symptoms.**

Most people can stop this around day 3.

Day 1: 0.5mg once

Day 2: 0.5mg twice a day

Day 3: 1mg twice a day


Day 4: 2mg twice a day

Day 5: 4mg twice a day

### Day 1

Take   0.5   mg   1   times today.

You will need to cut a 1/4 sized piece off a   2   mg film.




Ask your provider to demonstrate cutting films

### Day 2

Take   0.5   mg   2   times today.

You will need to cut two 1/4 sized pieces off a   2   mg film.




Ask your provider to demonstrate cutting films

**Day 3**

Take \_\_\_1\_\_\_ mg \_\_\_2\_\_\_ times today.


You will need to cut a \_\_\_2\_\_\_ mg film into \_\_\_2\_\_\_ pieces.



**Day 4**

Take \_\_\_2\_\_\_ mg \_\_\_2\_\_\_ times today.

You will take a whole 2 mg film twice today.




**NEW FILM prescription:**

**Day 5**

Take \_\_\_4\_\_\_ mg \_\_\_2\_\_\_ times today.

You will take 1/2 of a 8 mg film twice today.



**Day 6:**

8 mg films

take 8 mg 1-2 times a day depending on how you feel

## MN STYLE

- Day 1: 0.5mg once
- Day 2: 0.5mg twice a day
- Day 3: 1mg twice a day
- Day 4: 2mg twice a day
- Day 5: 4mg twice a day
- Day 6: 8-2 mg films BID

## BERNESE

- Day 1: 0.2 mg SL/2.5 g heroin
- Day 2: 0.2 mg SL/ 2 g heroin
- Day 3: 0.8+2 mg SL/ 0.5 g heroin
- Day 4: 2 +2.5 mg SL/ 1.5 g heroin
- Day 5: 2.5+2.5 mg SL/0.5 g heroin
- Day 6: 2.5 + 4 mg SL (stop heroin)
- Day 7: 4 + 4 mg SL
- Day 8: 8 + 4 mg SL



# Conclusions

- General harm reduction principals
  - Ensure patient has naloxone
  - Ensure patient has safer use supplies (clean needles, rigs, smoking supplies, et)
  - Ensure patient has information/education
  - Ensure patient remains connected even if they are not successful
    - Up to date contact information
  - Patients can do this on their own
    - Have information to give them



# Summary:

- Many medical providers think microinductions are not necessary
- There is not a “one size fits all” process to start suboxone
- There are many ways someone who uses drugs can use suboxone, depending on their own individual goal; and depending on how they are educated on its uses
- People who use opioids, and especially who use fentanyl, would benefit from multiple options on how to use suboxone, and discussing prior experience with precipitated withdrawal is key.
- Medical providers still are not sure who would benefit from classic induction, and who would benefit from the option of “microinduction”
- Research is ongoing on illicit fentanyl and MAT, but listening to people who use drugs is THE MOST important way to support them!



# Thank You!

- Questions?



UNIVERSITY OF MINNESOTA

Driven to Discover<sup>SM</sup>

# Microdosing citations

- Brar and Nolan, et al. Use of a novel prescribing approach for the treatment of opioid use disorder: Buprenorphine/naloxone micro-dosing – a case series. *Drug and Alcohol Review*, July 2020, 39, 588-594.
- Ghosh, SM. Et al. A Review of Novel Methods To Support The Transition From Methadone and Other Full Agonist Opioids To Buprenorphine/Naloxone Sublingual In Both Community and Acute Care Settings. *Canadian Journal of Addiction*, December 2019 - Volume 10 - Issue 4 - p 41-50.
- Greenwald, et al. Effects of Buprenorphine Maintenance Dose on m-Opioid Receptor Availability, Plasma Concentrations, and Antagonist Blockade in Heroin-Dependent Volunteers. *Neuropsychopharmacology* (2003) 28, 2000–2009.
- **Hammig, R., et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. *Subst Abuse Rehabil.* 2016; 7: 99–105.**
- Huhn AS, Hobelmann JG, Oyler GA, Strain EC. Protracted renal clearance of fentanyl in persons with opioid use disorder. *Drug Alcohol Depend.* 2020;214:108147.
- Terasaki, D., et al. Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol. (*Pharmacotherapy* 2019;39(10):1023–1029).



# Citations

- Brown RL, Leonard T, Saunders LA, Pappasoulitis O. The Prevalence and Detection of Substance Use Disorders among Inpatients Ages 18 to 49: An Opportunity for Prevention. *Prev Med.* 1998;27(1):101-110. doi:10.1006/pmed.1997.0250
- Caldiero et al. Inpatient Initiation of Buprenorphine Maintenance vs. Detoxification: Can Retention of Opioid-Dependent Patients in Outpatient Counseling Be Improved? *The American Journal on Addictions*, 15: 1–7, 2006. 1521-0391.
- D’Onofrio G, Chawarski MC, O’Connor PG, et al. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention. *J Gen Intern Med.*2017;32(6):660-666.
- Englander H, Weimer M, Solotaroff R, et al. Planning and Designing the Improving Addiction Care Team (IMPACT) for Hospitalized Adults with Substance Use Disorder. *J Hosp Med.* 2017;12(5):339-342.
- Gray et al. Rising rates of injection drug use associated infective endocarditis in Virginia with missed opportunities for addiction treatment referral: a retrospective cohort study. *BMC Infectious Diseases* (2018) 18:532.
- Ho J, Archuleta S, Sulaiman Z, Fisher D. Safe and successful treatment of intravenous drug users with a peripherally inserted central catheter in an outpatient parenteral antibiotic treatment service. 2010;(December 2009):2641-2644. doi:10.1093/jac/dkq355.
- Katz A, Goldberg D, Smith J, Trick WE. Tobacco, alcohol, and drug use among hospital patients: concurrent use and willingness to change. *J Hosp Med.* 2008;3(5):369-375. doi:10.1002/jhm.358
- Larochelle, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. A cohort study. *Annals of Internal Medicine.* June 19, 2018.
- Volkow, N. and Wargo, E. Overdose Prevention Through Medical Treatment of Opioid Use Disorders. *Annals of Internal Medicine.* June 19, 2018.
- Liebschutz JM, Crooks D, Herman D, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. *JAMA Intern Med.* 2014;174(8):1369-1376.
- <https://www.health.state.mn.us/people/syringe/ssp/index.htm>



# Citations...

- Marks et al. Addiction Medicine Consultations Reduce Readmission Rates for Patients With Serious Infections From Opioid Use Disorder. *Clinical Infectious Diseases*, 2019;68(11):1935–7.
- Noska et al. Managing Opioid Use Disorder During and After Acute Hospitalization: A Case-Based Review Clarifying Methadone Regulation for Acute Care Settings. *J Addict Behav Ther Rehabil*. 2015 ; 4(2): . doi:10.4172/2324-9005.1000138.
- O’Toole TP, Conde-Martel A, Young JH, Price J, Bigelow G, Ford DE. Managing acutely ill substance-abusing patients in an integrated day hospital outpatient program: medical therapies, complications, and overall treatment outcomes. *J Gen Intern Med*. 2006;21(6):570-576.
- Papalekas E, Patel N, Neph A, et al. ID WEEK 2014. 2014;1(Suppl 1):2014. doi:10.1093/o.
- Rodgman, C, Pletsch, G. Double successful buprenorphine/naloxone induction to facilitate cardiac transplantation in an iatrogenically opiate-dependent patient. *J Addict Med*. 2012 Jun;6(2):177-8.
- Rosenthal ES, Karchmer AW, Theisen-Toupal J, Castillo RA, Rowley CF. Suboptimal Addiction Interventions for Patients Hospitalized with Injection Drug Use-Associated Infective Endocarditis. *Am J Med*. 2016;129(5):481-485. doi:10.1016/j.amjmed.2015.09.024
- Safe II, History IDU, Therapy OA, Hospitalist T. Reference .2017;2016(7):1-5.
- Tice AD, Hoaglund PA, Nolet B, et al. Cost Perspectives for Outpatient Intravenous Antimicrobial Therapy.
- Tice AD, Rehm SJ, Dalovisio JR, et al. Practice Guidelines for Outpatient Parenteral Antimicrobial Therapy. 2004;38:1651-1672.
- Wurcel AG, Anderson JE, Chui KKH, et al. Increasing infectious endocarditis admissions among young people who inject drugs. *Open Forum Infect Dis*. 2016;3(3):ofw157. doi:10.1093/ofid/ofw157

